MeiHua Holdings Group (600873) Q4 2024 earnings summary

Executive summary

• Revenue for 2024 was RMB 25.07 billion, down 9.69% year-over-year, mainly due to lower selling prices for MSG, xanthan gum, and corn by-products, partially offset by higher sales of threonine, xanthan gum, and feed-grade valine.

• Net profit attributable to shareholders was RMB 2.74 billion, a 13.85% decrease year-over-year, impacted by a one-time RMB 233 million non-operating expense for litigation settlement.

• The company advanced its internationalization strategy, acquiring Kyowa Hakko Bio's pharmaceutical amino acid business and expanding production capacity for key products.

• MES system upgrades and digital transformation initiatives were implemented, with full MES deployment at the Baicheng facility and plans to extend to other plants.

• R&D investment reached RMB 733 million, focusing on synthetic biology, new strains, and process innovation.

Financial highlights

• Revenue: RMB 25.07 billion, down 9.69% year-over-year.

• Net profit attributable to shareholders: RMB 2.74 billion, down 13.85% year-over-year.

• Gross profit margin increased by 0.39 percentage points to 19.97%.

• Basic EPS: RMB 0.94, down from RMB 1.06 in 2023.

• Net cash flow from operating activities: RMB 4.63 billion, down 11.52% year-over-year.

• R&D spending: RMB 733 million, 2.93% of revenue.

Outlook and guidance

• Plans to deepen global expansion, including new overseas production bases and further integration of acquired Kyowa Hakko assets.

• Continued MES system rollout and digital transformation across all production sites.

• Focus on synthetic biology, capacity expansion for lysine, threonine, and valine, and further R&D investment.

• Ongoing risk management in response to global trade protectionism and anti-dumping investigations.